The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
Open accessAbstract
Background and Purpose— Warfarin is the most effective stroke prevention medication for high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the magnitude of this problem in a large contemporary, prospective stroke registry. Methods— We analyzed data from the Registry of the Canadian Stroke Network, a prospective database of consecutive patients with stroke admitted to 12 designated stroke centers in Ontario (2003 to 2007). We included patients admitted with an acute ischemic stroke who (1) had a known history of atrial fibrillation; (2) were classified as high risk for systemic emboli according to published guidelines; and (3) had no known contraindications to anticoagulation. Primary end points were the use of prestroke antithrombotic medications and admission international normalized ratio. Results— Among patients admitted with a first ischemic stroke who had known atrial fibrillation (n=597), strokes were disabling in 60% and fatal in 20%. Preadmission medications were warfarin (40%), antiplatelet therapy (30%), and no antithrombotics (29%). Of those taking warfarin, three fourths had a subtherapeutic international normalized ratio (<2.0) at the time of stroke admission. Overall, only 10% of patients with acute stroke with known atrial fibrillation were therapeutically anticoagulated (international normalized ratio ≥2.0) at admission. In stroke patients with a history of atrial fibrillation and a previous transient ischemic attack or ischemic stroke (n=323), only 18% were taking warfarin with therapeutic international normalized ratio at the time of admission for stroke, 39% were taking warfarin with subtherapeutic international normalized ratio, and 15% were on no antithrombotic therapy. Conclusions— In high-risk patients with atrial fibrillation admitted with a stroke, and who were candidates for anticoagulation, most were either not taking warfarin or were subtherapeutic at the time of ischemic stroke. Many were on no antithrombotic therapy. These findings should encourage greater efforts to prescribe and monitor appropriate antithrombotic therapy to prevent stroke in individuals with atrial fibrillation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., & Carolei, A. (2005) · Stroke · doi:10.1161/01.str.0000166053.83476.4a · Cited by 949 · cited 2×
“We included patients admitted with an acute ischemic stroke who (1) had a known history of atrial fibrillation; (2) were classified as high risk for systemic emboli according to published guidelines; and (3) had no known contraindications to anticoagulation.”
BackgroundMethodWhy Do Patients With Atrial Fibrillation Not Receive Warfarin?
Bungard, T. J., Ghali, W. A., Teo, K. K., McAlister, F. A., & Tsuyuki, R. T. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.41 · Cited by 593
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK
Stewart, S., Murphy, N., Walker, A., McGuire, A., & McMurray, J. J. V. (2004) · Heart · doi:10.1136/hrt.2002.008748 · Cited by 590
Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.7.677 · Cited by 538
Self-citation
Cited by
Atrial fibrillation in patients with cryptogenic stroke
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, H., O'Donnell, M., Laupacis, A., Côté, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311376 · Cited by 1,276
Self-citationThe Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Singer, D. E., Chang, Y., Fang, M. C., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Go, A. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00003 · Cited by 656
Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration
Freedman, B., Camm, J., Calkins, H., Healey, J. S., Rosenqvist, M., Wang, J., Albert, C. M., Anderson, C. S., Antoniou, S., Benjamin, E. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026693 · Cited by 537
Self-citationLane, D. A., & Lip, G. Y. H. (2012) · Circulation · doi:10.1161/circulationaha.111.060061 · Cited by 388
Chiang, C.-E., Naditch-Brûlé, L., Murin, J., Goethals, M., Inoue, H., O’Neill, J., Silva-Cardoso, J., Zharinov, O., Gamra, H., Alam, S., et al. (2012) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.112.970749 · Cited by 327
Metadata
- Authors
- Gladstone, D. J., Bui, E., Fang, J., Laupacis, A., Lindsay, M. P., Tu, J. V., Silver, F. L., & Kapral, M. K.
- Venue
- Stroke
- Published
- 2009-01
- Volume
- 40
- Issue
- 1
- Pages
- 235-240
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2104343448
- Cited by
- 402
- References
- 39
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated. https://app.cochat.ai/papers/10.1161/strokeaha.108.516344
- The paper
- Gladstone, D. J., Bui, E., Fang, J., Laupacis, A., Lindsay, M. P., Tu, J. V., Silver, F. L., & Kapral, M. K. (2009). Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated. Stroke. https://doi.org/10.1161/strokeaha.108.516344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.